Published online before print September 2, 2008, doi: 10.1161/HYPERTENSIONAHA.108.114587
(Hypertension. 2008;52:715.)
© 2008 American Heart Association, Inc.
Original Articles |
Tissue Kallikrein Elicits Cardioprotection by Direct Kinin B2 Receptor Activation Independent of Kinin Formation
From the Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston.
Correspondence to Julie Chao, PhD, Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 173 Ashley Ave, Charleston, SC 29425. E-mail chaoj{at}musc.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Tissue kallikrein exerts various biological functions through kinin formation with subsequent kinin B2 receptor activation. Recent studies showed that tissue kallikrein directly activates kinin B2 receptor in cultured cells expressing human kinin B2 receptor. In the present study, we investigated the role of tissue kallikrein in protection against cardiac injury through direct kinin B2 receptor activation using kininogen-deficient Brown Norway Katholiek rats after acute myocardial infarction. Tissue kallikrein was injected locally into the myocardium of Brown Norway Katholiek rats after coronary artery ligation with and without coinjection of icatibant (a kinin B2 receptor antagonist) and N
-nitro-L-arginine methylester (an NO synthase inhibitor). One day after myocardial infarction, tissue kallikrein treatment significantly improved cardiac contractility and reduced myocardial infarct size and left ventricle end diastolic pressure in Brown Norway Katholiek rats. Kallikrein attenuated ischemia-induced apoptosis and monocyte/macrophage accumulation in the ischemic myocardium in conjunction with increased NO levels and reduced myeloperoxidase activity. Icatibant and N-nitro-L-arginine methylester abolished kallikrein’s effects, indicating a kinin B2 receptor NO-mediated event. Moreover, inactive kallikrein had no beneficial effects in cardiac function, myocardial infarction, apoptosis, or inflammatory cell infiltration after myocardial infarction. In primary cardiomyocytes derived from Brown Norway Katholiek rats under serum-free conditions, active, but not inactive, kallikrein reduced hypoxia/reoxygenation-induced apoptosis and caspase-3 activity, and the effects were mediated by kinin B2 receptor/nitric oxide formation. This is the first study to demonstrate that tissue kallikrein directly activates kinin B2 receptor in the absence of kininogen to reduce infarct size, apoptosis, and inflammation and improve cardiac performance of infarcted hearts.
Key Words: apoptosis • cardiac function • infarct size • kinin B2 receptor • tissue kallikrein
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Tissue kallikrein is a serine proteinase that specifically processes low-molecular-weight kininogen to produce the potent vasoactive kinin peptides bradykinin and Lys-bradykinin (kallidin),1 which bind to and activate the kinin B2 receptor.2 Kinins have been shown to protect against cardiac injury through kinin B2 receptor activation.3,4 Yang and coworkers5 demonstrated that the cardioprotective effect of preconditioning was abolished in kinin B2 receptor knockout mice and in kininogen-deficient rats. The cardioprotective response to inhibition of angiotensin-converting enzyme (ACE) and angiotensin II type 1 receptor was diminished in B2 receptor-deficient mice.6 Similarly, kinins appear to play an important role in the cardioprotective effect of ACE inhibition in kininogen-deficient rats.7 However, recent studies from Erdös’ group demonstrated that tissue kallikrein directly activates the kinin B2 receptor in cultured Chinese hamster ovary cells.8,9 This novel finding is consistent with our earlier report that tissue kallikrein directly induced rat uterine contraction independent of detectable kinin formation.10 In contrast, contraction of isolated jugular vein by tissue kallikrein appears to be dependent on blood vessel-derived kininogen and B2 receptor activation.11 Taken together, these results indicate that tissue kallikrein’s actions are mediated by kinin B2 receptor activation with or without kinin formation. However, whether tissue kallikrein can directly act on the kinin B2 receptor in the absence of kinin formation in triggering cardioprotective effects in vivo has not been demonstrated.
Brown Norway Katholiek (BNK) rats, genetically deficient in kininogen secretion, retain kinin B2 receptor expression. Therefore, the kininogen-deficient BNK rat is an ideal model to investigate whether tissue kallikrein has a direct effect on kinin B2 receptor in triggering biological functions. In this study, we determined whether tissue kallikrein has a cardioprotective role by direct activation of the kinin B2 receptor in BNK rats after myocardial infarction (MI). Our results showed that tissue kallikrein through kinin B2 receptor activation and NO formation improved cardiac performance and reduced ischemia-induced infarction, cardiomyocyte apoptosis, and intramyocardial inflammation in BNK rats. This is the first study to identify a direct biological function of tissue kallikrein through kinin B2 receptor activation independent of kinin formation in vivo.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals and Treatments
Brown Norway Katholiek rats were kindly provided by Dr Edward Shesely of Hypertension and Vascular Research Division, Henry Ford Hospital (Detroit, Mich) and were initially obtained from the Department of Pharmacology, Kitasato University School of Medicine. Male BNK rats weighing 200 to 250 g were subjected to ligation of the left coronary artery as previously described.12 This study complied with the Guides for the Care and Use of Laboratory Animals (Institute of Laboratory Resources, National Academy of Sciences). Rat tissue kallikrein was purified and characterized as previously described.13 Animals were randomly divided into 6 groups (n=10 in each group). In 2 control groups, rats were subjected to either sham surgery or left anterior descending coronary artery ligation followed by saline injection. In the third group, tissue kallikrein (25 µg in 150 µL saline) was injected at 7 different sites into the border area of the infarcted left ventricle immediately after coronary artery ligation. The fourth group received tissue kallikrein together with coinjection of the kinin B2 receptor antagonist (icatibant, 15 µg/rat; obtained from Hoechst Marion Roussel). The fifth group received tissue kallikrein followed by intravenous injection of N
-nitro-L-arginine-methyl-ester (L-NAME) (35 mg/kg). The sixth group received inactive tissue kallikrein in a similar manner. One day after coronary artery ligation, hemodynamic parameters were analyzed as previously described,14 animals were euthanized, and heart tissues were harvested for morphological and biochemical analyses.
Inactivation of Tissue Kallikrein by Aprotinin
Tissue kallikrein was inactivated by prior incubation with 5-fold molar excess of aprotinin at 37°C for 1 hour. Inactivation of tissue kallikrein was determined by enzymatic assay with S2266, a chromogenic substrate.15 Aprotinin-treated tissue kallikrein exhibited less than 5% of active kallikrein activity.
Myocardial Infarct Size Determination
The middle part of the heart (2 mm) was sectioned transversely and incubated with 1.5% 2,3,5-triphenyltetrazolium chloride (Sigma) for 5 minutes at 37°C. The ratio of infarcted area to the area at risk was then calculated. The infarcted area was distinguished by 2,3,5-triphenyltetrazolium chloride staining using computer-assisted planimetry (National Institutes of Health Image 1.57).
Histological and Immunohistological Analysis
For histological analyses, the left ventricle was fixed with 4% paraformaldehyde, dehydrated, embedded, and cut into 4-µm sections. Primary antibody against ED-1 (Chemicon, 1:200) was used for immunostaining of monocytes/macrophages. The number of ED-1-positive cells was counted in a double-blind fashion from 8 to 10 different fields of each section (n=10) at 400x magnification. Apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling).16 The ratio of terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling-positive cardiomyocytes to the total number of cardiomyocytes was calculated.
Hypoxia/Reoxygenation of Primary Cultured Cardiomyocytes
Cardiomyocytes were isolated from the hearts of 2- to 3-day-old BNK rats as previously described.17 Cardiomyocytes were grown in DMEM supplemented with 10% fetal bovine serum. Cardiomyocyte origin was confirmed immunocytochemically using antibody to sarcomeric 
-actinin (Sigma). Subcultured cells were maintained in serum-free DMEM for 24 hours and then incubated with serum-free DMEM supplemented with active tissue kallikrein (0.2 µmol/L) or aprotinin-inactivated tissue kallikrein (0.2 µmol/L) under the condition of hypoxia for 12 hours (95% N2 and 5% CO2) followed by 24-hour reoxygenation (95% O2 and 5% CO2). Apoptotic cardiomyocytes were identified by Hoechst 33342 staining. Hoechst-positive apoptotic cells were determined by counting cardiomyocytes in 6 randomly chosen fields. Caspase-3 activity in cardiomyocyte lysates was determined using a fluorometric caspase-3 assay kit (Oncogene) according to the manufacturer’s instructions.
Nitrate/Nitrite and Myeloperoxidase Assays
Nitrate/nitrite levels, an indicator of NO production, were measured by a fluorometric assay as previously described.18 Myeloperoxidase activity in cardiac extracts was measured as previously described.19
Statistical Analysis
Data were compared among experimental groups using analysis of variance followed by Fisher’s partial least squares difference. Data are expressed as mean±SEM. Differences were considered statistically significant at a value of P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Kallikrein Improves Cardiac Function and Reduces Infarct Size in Kininogen-Deficient Rats
Tissue kallikrein injection significantly improved cardiac function in BNK rats 1 day after MI (Table). MI induced a significant increase of left ventricular end diastolic pressure compared with the sham group, whereas kallikrein significantly reduced left ventricular end diastolic pressure. Cardiac contractility (dP/dt max and dP/dt min) was markedly reduced after MI, but was significantly increased by kallikrein. Both icatibant and L-NAME blocked kallikrein’s cardioprotective effects. Unlike active kallikrein, aprotinin-inactivated kallikrein did not improve cardiac contractility or reduce left ventricular end diastolic pressure in BNK rats after MI. Mean arterial pressure was not altered among all groups.
|
Intramyocardial injection of tissue kallikrein, but not inactive kallikrein, significantly reduced infarct size in the left ventricle 1 day after MI compared with the MI control group, as determined by 2,3,5-triphenyltetrazolium chloride staining and quantitative analysis (Figure 1A and 1B). Coadministration of icatibant and L-NAME abrogated kallikrein’s effect. However, icatibant, L-NAME, or aprotinin alone had no effect on myocardial infarct size as compared with the MI control (data not shown).
|
Kallikrein Reduces MI-Induced Cardiomyocyte Apoptosis and Intramyocardial Inflammation
Apoptotic cardiomyocytes were detected by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling staining in the infarcted myocardium 1 day after MI, and kallikrein treatment reduced the number of apoptotic cells (Figure 2A). Icatibant and L-NAME abrogated kallikrein’s effect, and inactive kallikrein had no effect. Quantitative analysis showed that active, but not inactive, kallikrein significantly reduced the ratio of terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling-positive cardiomyocytes to total number of cardiomyocytes as compared with the control group. However, kallikrein’s protective effect was blocked by icatibant and L-NAME (Figure 2B). Furthermore, inflammatory cell accumulation in the infarcted region of the heart was identified by ED-1 immunostaining (Figure 3A). ED-1 positive cells were counted for quantification of monocyte/macrophage number (Figure 3B). Increased inflammatory cell infiltration was detected in the infarcted area of the heart after acute MI, but kallikrein injection significantly decreased monocytes/macrophages compared with the control. Icatibant and L-NAME blocked kallikrein’s effect, but aprotinin-inactivated kallikrein had no protective effect against the inflammatory response.
|
|
Kallikrein Increases NO Levels and Reduces Myeloperoxidase Activity
Kallikrein treatment resulted in a significant increase in cardiac nitrate/nitrite production compared with the MI control group, and this effect was abrogated by icatibant and L-NAME (Figure 4A). Moreover, kallikrein prevented the increase in cardiac myeloperoxidase levels induced by MI damage, and the effect of kallikrein was blocked by icatibant and L-NAME (Figure 4B). Again, inactive kallikrein had no effect in increasing NO formation or inhibiting oxidative stress.
|
Active Kallikrein Reduces Hypoxia/Reoxygenation-Induced Apoptosis and Caspase-3 Activity in Primary Cultured Cardiomyocytes
Representative Hoechst-positive staining and quantitative analysis showed that active tissue kallikrein, but not aprotinin-inactivated tissue kallikrein, significantly reduced hypoxia/reoxygenation-induced apoptosis in cultured primary cardiomyocytes derived from BNK rats (Figure 5A and 5B). Similarly, active kallikrein, but not inactive kallikrein, significantly reduced hypoxia/reoxygenation-induced caspase-3 activity (Figure 5C). Icatibant and L-NAME abrogated kallikrein’s effects on both apoptosis and caspase-3 activity.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This study establishes that tissue kallikrein elicits cardioprotection independent of kinin formation. Using kininogen-deficient BNK rats, which are unable to produce kinin peptides,7 we clearly demonstrated that tissue kallikrein has a direct role in protection against cardiac injury by reducing MI-induced infarct size, cardiomyocyte apoptosis, and intramyocardial inflammation through kinin B2 receptor activation and NO formation. Similar results were observed from our previous studies using kininogen-expressing Wistar rats subjected to MI.14 More than 2 decades ago, we reported that tissue kallikrein rapidly induced rat uterine contraction despite kinin antiserum and kininase treatment.10 In addition, Erdös’ group8 reported that kallikrein can trigger kinin B2 receptor activation independent of kinin formation in cultured cells. Thus, our present study confirmed those previous studies. Moreover, ACE inhibition has been shown to potentiate kallikrein’s effect on kinin B2 receptor activation in the absence of kinin formation.9 Because ACE inhibitors are popular drugs used in the treatment of cardiovascular and related diseases, the current findings suggest that kallikrein may also contribute to the therapeutic effects of ACE inhibition through a kininogen/kinin-independent pathway. Taken together, these combined results indicate that tissue kallikrein has a direct function independent of its kinin-releasing activity in protection against cardiovascular disease. It is important to note that the involvement of local cardiac low-molecular-weight kininogens in BNK rats can be dismissed due to the finding that this rat strain possesses a point mutation in the kininogen gene that causes low-molecular-weight kininogen to accumulate inside the cell and thus prevent its secretion for cleavage by kallikrein.20 Moreover, rat T-kininogen should have no effect on our observations because it cannot be cleaved by tissue kallikrein.21
It has been shown that only active tissue kallikrein, but not active site-inhibited kallikrein, can stimulate the kinin B2 receptor in cultured cells, suggesting that cleavage of a peptide bond in the receptor is necessary for its activation by kallikrein.8 To determine whether tissue kallikrein has a direct proteolytic action on the kinin B2 receptor, we evaluated the effect of purified active and inactive forms of tissue kallikrein on hypoxia/reoxygenation-induced programmed cell death in cultured cardiomyocytes. Our results showed that active kallikrein, but not inactive kallikrein, inhibited hypoxia-induced apoptosis and caspase-3 activity in cultured cardiomyocytes derived from Sprague-Dawley (data not shown) and kininogen-deficient rats. These results indeed indicate that cleavage of a peptide bond in the kinin B2 receptor is necessary for direct activation of kinin B2 receptor by tissue kallikrein.
Kinin is capable of generating NO by causing an increase in the phosphorylation of endothelial NO synthase.22 Similarly, tissue kallikrein gene transfer has been shown to promote muscular neovascularization by endothelial NO synthase upregulation and Akt activation.23 Moreover, endothelial NO synthase gene delivery protected against cardiac remodeling through reduction of oxidative stress after MI.24 NO is a potent antioxidant25 and is capable of inhibiting neutrophil superoxide anion production through a direct action on the membrane components of NADPH oxidase and the assembly of NADH/NADPH oxidase subunits.26,27 Our present finding showed that icatibant and L-NAME abolished kallikrein’s effects in promoting nitrate/nitrite (an indicator of NO) levels as well as suppressing superoxide production in infarcted hearts. These combined results indicate that kallikrein/kinin is capable of improving cardiac function through increased NO formation.
A recent study showed that the kinin B1 and B2 receptors may serve a protective role in cardiac dysfunction.28 However, we previously demonstrated that myocardial hypertrophy induced by aortic occlusion is mediated by B2 receptor, but not by B1 receptor, using kinin receptor knockout mice.29 In addition, intact bradykinin, but not des-Arg9-bradykinin (a kinin B1 receptor agonist), prevented cardiomyocyte apoptosis and ventricular remodeling after acute ischemia/reperfusion, supporting a role of kinin B2 receptor, but not B1 receptor, in cardiac protection.3 The potential role of tissue kallikrein in protection against other organ damage such as the kidney, blood vessels, and brain through direct kinin B2 receptor activation awaits further investigation.
It has been recently reported that the kallikrein–kinin system is involved in protease-activated receptor-mediated inflammation in rodents.30 In this regard, we observed that tissue kallikrein independent of kinin formation promotes the migration of cultured human keratinocytes through direct activation of protease-activated receptor-1 (Gao L, Chao L, Chao J, unpublished results). Whether tissue kallikrein can act on protease-activated receptors to prevent ischemic heart disease, independent of its interaction with kinin receptors, is a new avenue for future studies.
Perspectives
This is the first study to demonstrate that tissue kallikrein improves cardiac function by inhibiting apoptosis and inflammation through direct activation of the kinin B2 receptor without kinin formation in the infarcted myocardium. Comparison of active and inactive tissue kallikrein indicates that cleavage of a peptide bond is required for B2 receptor stimulation by kallikrein in vitro and in vivo. This is an innovative finding because it is well characterized that tissue kallikrein exerts biological functions through generation of kinin peptides from kininogen substrate. Because ACE inhibition can potentiate kallikrein’s effect on kinin B2 receptor activation, tissue kallikrein, in addition to kinin formation, could provide advanced therapeutic benefits of ACE inhibition in protection against cardiovascular and renal diseases.
|
Acknowledgments |
|---|
Sources of Funding
This work was supported by National Institutes of Health grants HL29397, DK066350, and C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources.
Disclosures
None.
Received April 9, 2008; first decision May 6, 2008; accepted August 1, 2008.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992; 44: 1–80.[Medline] [Order article via Infotrieve]
2. Regoli D, Rhaleb NE, Drapeau G, Dion S. Kinin receptor subtypes. J Cardiovasc Pharmacol. 1990; 15: S30–S38.
3. Yin H, Chao J, Bader M, Chao L. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides. 2007; 28: 1383–1389.[CrossRef][Medline] [Order article via Infotrieve]
4. Linz W, Wiemer G, Gohlke P, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995; 47: 25–49.[Abstract]
5. Yang XP, Liu YH, Scicli GM, Webb CR, Carretero OA. Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension. 1997; 30: 735–740.
6. Yang XP, Liu YH, Mehta D, Cavasin MA, Shesely E, Xu J, Liu F, Carretero OA. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B2 kinin receptor gene knockout mice. Circ Res. 2001; 88: 1072–1079.
7. Liu YH, Yang XP, Mehta D, Bulagannawar M, Scicli GM, Carretero OA. Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats. Am J Physiol Heart Circ Physiol. 2000; 278: H507–H514.
8. Hecquet C, Tan F, Marcic BM, Erdös EG. Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. Mol Pharmacol. 2000; 58: 828–836.
9. Biyashev D, Tan F, Chen Z, Zhang K, Deddish PA, Erdös EG, Hecquet C. Kallikrein activates bradykinin B2 receptors in absence of kininogen. Am J Physiol Heart Circ Physiol. 2006; 290: H1244–H1250.
10. Chao J, Buse J, Shimamoto K, Margolius HS. Kallikrein-induced uterine contraction independent of kinin formation. Proc Natl Acad Sci U S A. 1981; 78: 6154–6157.
11. Houle S, Molinaro G, Adam A, Marceau F. Tissue kallikrein actions at the rabbit natural or recombinant kinin B2 receptors. Hypertension. 2003; 41: 611–617.
12. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res. 1979; 44: 503–512.
13. Chao J, Margolius HS. Isozymes of rat urinary kallikrein. Biochem Pharmacol. 1979; 28: 2071–2079.[CrossRef][Medline] [Order article via Infotrieve]
14. Agata J, Chao L, Chao J. Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension. 2002; 40: 653–659.
15. Berg T, Johansen L, and Nustad K. Enzymatic activity of rat submandibular gland kallikrein released into blood. Am J Physiol Heart Circ Physiol. 1985; 249: H1134–H1142.
16. Yin H, Chao L, Chao J. Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad. 14-3-3 signaling pathways. J Biol Chem. 2005; 280: 8022–8030.
17. Kaiser RA, Bueno OF, Lips DJ, Doevendans PA, Jones F, Kimball TF, Molkentin JD. Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia–reperfusion in vivo. J Biol Chem. 2004; 279: 15524–15530.
18. Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem. 1993; 214: 11–16.[CrossRef][Medline] [Order article via Infotrieve]
19. Suzuki K, Ota H, Sasagawa S, Sakatani T, Fujikura T. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem. 1983; 132: 345–352.[CrossRef][Medline] [Order article via Infotrieve]
20. Oh-ishi S, Hayashi I, Hosiko S, Makabe O. Molecular mechanism of kininogen deficiency in brown Norway Katholiek rats. Braz J Med Biol Res. 1994; 27: 1803–1815.[Medline] [Order article via Infotrieve]
21. Chagas JR, Hirata IY, Juliano MA, Xiong W, Wang C, Chao J, Juliano L, Prado ES. Substrate specificities of tissue kallikrein and T-kininogenase: their possible role in kininogen processing. Biochemistry. 1992; 31: 4969–4974.[CrossRef][Medline] [Order article via Infotrieve]
22. Harris MB, Ju H, Venema VJ, Liang H, Zou R, Michell BJ, Chen ZP, Kemp BE, Venema RC. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem. 2001; 276: 16587–16591.
23. Emanueli C, Salis MB, Linthout SV, Meloni M, Desortes E, Silvestre JS. Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation. 2004; 110: 1638–1644.
24. Smith RS Jr, Agata J, Xia CF, Chao L, Chao J. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci. 2005; 76: 2457–2471.[CrossRef][Medline] [Order article via Infotrieve]
25. Xu Z, Park SS, Mueller RA, Bagnell RC, Patterson C, Boysen PG. Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes. Cardiovasc Res. 2005; 65: 803–812.
26. Clancy RM, Leszczynska-Pizizk J, Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest. 1992; 90: 1116–11121.[Medline] [Order article via Infotrieve]
27. Fujii H, Ichimori K, Hoshiai K, Nakazawa H. Nitric oxide inactivates NADPH oxidase in pig neutrophils by inhibiting its assembling process. J Biol Chem. 1997; 272: 32773–32778.
28. Xu J, Carretero OA, Sun Y, Shesely EG, Rhaleb NE, Liu YH, Liao TD, Yang JJ, Bader M, Yang XP. Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension. 2005; 45: 747–753.
29. Li HJ, Yin H, Yao YY, Shen B, Bader M, Chao L, Chao J. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res. 2007; 73: 130–142.
30. Houle S, Papez MD, Ferazzini M, Hollenberg MD, Vergnolle N. Neutrophils and the kallikrein–kinin system in protease-activated receptor 4-mediated inflammation in rodents. Br J Pharmacol. 2005; 146: 670–678.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  E. G. Erdos, F. Tan, and R. A. Skidgel Angiotensin I-Converting Enzyme Inhibitors Are Allosteric Enhancers of Kinin B1 and B2 Receptor Function Hypertension, February 1, 2010; 55(2): 214 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Westermann, T. Walther, K. Savvatis, F. Escher, M. Sobirey, A. Riad, M. Bader, H.-P. Schultheiss, and C. Tschope Gene Deletion of the Kinin Receptor B1 Attenuates Cardiac Inflammation and Fibrosis During the Development of Experimental Diabetic Cardiomyopathy Diabetes, June 1, 2009; 58(6): 1373 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. A. Stone, C. Richer, C. Emanueli, V. van Weel, P. H.A. Quax, R. Katare, N. Kraenkel, P. Campagnolo, L. S. Barcelos, M. Siragusa, et al. Critical Role of Tissue Kallikrein in Vessel Formation and Maturation: Implications for Therapeutic Revascularization Arterioscler Thromb Vasc Biol, May 1, 2009; 29(5): 657 - 664. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||